22 November 2024

Starpharma's new formulations demonstrate further improvement in crop protection

  • New dendrimer-glyphosate formulations demonstrate improved efficacy and rain-fastness
  • Higher loading formulations and soil penetration achieved
  • Dendrimers applicable to a wide range of agrochemical products

Melbourne, Australia:  Starpharma Holdings Ltd (ASX:SPL;OTCQX: SPHRY) today announced that its new agrochemical dendrimer formulations have shown further improved features compared to commercially available products.

Starpharma has conducted a whole range of new studies in its internal agrochemical program including with its lead program, an enhanced reformulation of the best-selling herbicide glyphosate (marketed under a variety of trade names including Roundup®).

The new dendrimer glyphosate reformulations have confirmed previously reported higher efficacy than existing marketed glyphosate formulations. The significance of these new results is in the potential to further broaden the conditions under which the Starpharma glyphosate formulation is effective, such as in adverse environments. 

In addition to the improved efficacy referred to above, Starpharma has also recently shown its formulations to be more rain-fast compared to glyphosate formulations without dendrimer.  Starpharma’s dendrimer formulations demonstrated up to a 150%-250% improvement in efficacy when rain was applied four hours after treatment with the test formulations.

Glyphosate has global sales of approximately US$5 billion annually and as an off-patent chemical represents the largest opportunity for an enhanced formulation in the US$44 billion* agrochemical market.

“In addition to improving major products such as glyphosate, there are crop protection products with sales of more than $5 billion which will come off patent in the next 4-5 years. This creates a significant commercial opportunity for Starpharma’s dendrimers to deliver improved, proprietary formulations to this large and growing market,” said Dr Jackie Fairley, Chief Executive Officer.

Other recent formulation activities at Starpharma have been targeted at improving the loading of commercially important crop protection products.  Using formulations that include dendrimers, Starpharma has increased the loading of one important herbicide by 50% more than formulations currently available in the market. High loading formulations generally have an improved cost of goods by reducing transport and handling costs and are sought after by both farmers and crop protection companies.

Soil penetration is also important for the performance of some crop protection products to ensure that they reach their targets.  In laboratory studies using imidacloprid, a US$1BN product, Starpharma has shown that its dendrimers can tailor how this important insecticide moves by either increasing or decreasing percolation through a substrate. Common uses of imidacloprid include termite control and the control of other soil inhabiting insects.

In addition to its internal programs Starpharma continues to advance existing agrochemical partnerships, and in August announced a new Crop Protection Agreement with Nufarm. Nufarm is one of the world’s leading crop protection companies with sales in excess of A$2billion.

Starpharma’s agrochemicals program has been assisted by funding under the Victorian Government’s Small Technology Industries Uptake Program (STIUP), and research is also ongoing in partnership with a number of global agrochemical companies. 

*CropLife US, Phillips McDougal data

Download ASX Announcement:   New formulations demonstrate further improvement in crop protection ( pdf file, 269kb)


This contains certain forward-looking statements.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.